Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity

C Hahmann; T Schroeter

doi:10.1007/s00018-009-0189-x

Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity

Cell Mol Life Sci. 2010 Jan;67(2):171-7. doi: 10.1007/s00018-009-0189-x. Epub 2009 Nov 12.

Authors

C Hahmann¹, T Schroeter

Affiliation

¹ Discovery Biology, Translational Research Institute, The Scripps Research Institute, Scripps Florida, 130 Scripps Way, Jupiter, FL 33458, USA.

PMID: 19907920
DOI: 10.1007/s00018-009-0189-x

Abstract

The emerging critical implications of Rho/Rho-kinase (ROCK) signaling in neurodegenerative diseases, glaucoma, renoprotection, diabetes and cancer have sparked growing interest in the pharmacological potential of ROCK inhibitors beyond their current application in cardiovascular disease. This article discusses the therapeutic benefits of novel ROCK inhibitors in development, and highlights the recent advances in the current understanding of disease-dependent and isoform-specific functions of ROCK and their potential impact on future therapeutic strategies.

Publication types

Review

MeSH terms

Animals
Diabetes Mellitus / drug therapy*
Diabetes Mellitus / enzymology
Dogs
Glaucoma / drug therapy*
Glaucoma / enzymology
Humans
Isoenzymes / antagonists & inhibitors
Isoenzymes / chemistry
Kidney Diseases / drug therapy*
Kidney Diseases / enzymology
Mice
Neoplasms / drug therapy*
Neoplasms / enzymology
Neurodegenerative Diseases / drug therapy*
Neurodegenerative Diseases / enzymology
Protein Kinase Inhibitors / chemistry
Protein Kinase Inhibitors / therapeutic use*
Rats
rho-Associated Kinases / antagonists & inhibitors*
rho-Associated Kinases / chemistry

Substances

Isoenzymes
Protein Kinase Inhibitors
rho-Associated Kinases